• Alias: AMN107
    • Orally bioavailable BCR-ABL, KIT inhibitor
    • FDA approved for (a) newly diagnosed Philadelphia chromosome–positive chronic myelogenous leukemia (Ph+ CML) in chronic phase, and (b) chronic phase and accelerated phase Ph+ CML in adult patients resistant to or intolerant to prior therapy that included imatinib
    • Recommended dose: (a) 300 mg PO twice daily; (b) 400 mg PO twice daily
    • Half-life: 17 hours
    • Metabolism: CYP2D6, CYP2C9, CYP2C19, CYP1A2, NAT2, and DPD substrate
    • Common side effects: QT prolongation (US box warning); nonhematologic: Rash, pruritus, headache, nausea, fatigue, myalgia, nasopharyngitis, constipation, diarrhea, abdominal pain, pyrexia, upper respiratory tract infection, back pain, cough, and asthenia;
    Other topics in Targeted and Immunotherapy Agents